152-OR: Glargine Timing during Fasting Ramadan in Patients with Type 1 Diabetes: A Randomized Controlled Trial
| العنوان: | 152-OR: Glargine Timing during Fasting Ramadan in Patients with Type 1 Diabetes: A Randomized Controlled Trial |
|---|---|
| المؤلفون: | Yousef M. Saleh, Salwa Alaidarous, Reem Alamoudi, Abdulrhman Aljawhrji, Mohamed Hassanein, Hawazen A. Zarif, Ghofran S. Khogeer, Maram Alsubaiee, Seham A. Khashwayn, Ali Al Qarni |
| المصدر: | Diabetes. 70 |
| بيانات النشر: | American Diabetes Association, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Type 1 diabetes, Evening, business.industry, Endocrinology, Diabetes and Metabolism, Hypoglycemia, medicine.disease, Bedtime, law.invention, Randomized controlled trial, law, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, In patient, business, Morning |
| الوصف: | IDF-DaR guidelines recommend change of basal insulin timing to early evening. Randomized trials examining timing of basal insulin during fasting are lacking. Objective: To compare glucose profiles in T1DM patients taking Glargine at early evening (6-7 pm) versus bedtime (10-12 night) during fasting Ramadan. Methods: Multicenter open label randomized controlled trial. Patients recruited in 4 centers from 4 cities in Saudi Arabia. Data collected using pre- and post-Ramadan questioners. Glucose data collected via self-monitoring (Roche AccuCheck glucometer/the Abbott Freestyle Libre), and Envision iPro CGM. Results: 185 T1DM patients randomized; 91 to glargine at 6-7pm (early), and 94 at 10-12 night (late). 32.4% ≤18 years, 53% female, and average duration of DM 11 ±11. No significant differences between the two groups in demographics or DM complications. Early vs. late group: Pre Ramadan A1c 9 ±2.7 vs. 8.75 ±2.1, p=0.35, post Ramadan A1c 8.4 ±2.9 vs. 8.7 ±2.7, p=0.5. Breaking of fast reported in 66 (75.9%) vs. 71 (76.3%), p=0.94; average number of days 4±6 vs. 4±4, p=0.5, and due to hypoglycemia in >90% of cases for both groups. Hypoglycemia most common in Morning 32 (59.3%) vs. 38 (60.35%), p=0.85. Severe hypoglycemia reported in 2 vs. 5 patients, and 1 DKA admission in each group. Combined CGM data during Ramadan: A1c 7.6 ±1.7 vs. 7.7 ±2.1, p=0.63. Average Time in range of 70-180 mg/dl 44.6% vs. 46.1%, p=0.7, Time below range (180mg/dl) 47.5 vs. 47.5%, p=0.99. Total hypoglycemic episodes detected by SMBG 4 ±6 vs. 3 ±8, p=0.3, and Low excursions detected by iPro CGM 5 ±6 vs. 4 ±5.5, p=0.22, with AUC below limit 0.5 ±1 vs. 0.15 ±0.85, p=0.03. Conclusion: Changing glargine timing during Ramadan to early evening hours carries no significant advantage over keeping at bedtime in regards to hypoglycemia and overall glucose profiles. ClinicalTrials.gov: NCT04383990. Disclosure R. Alamoudi: None. M. Hassanein: None. G. S. Khogeer: None. A. Al qarni: None. Y. M. Saleh: Advisory Panel; Self; American Association of Clinical Endocrinologists, Boehringer Ingelheim Pharmaceuticals, Inc., Novo Nordisk, Research Support; Self; Servier Laboratories, Speaker’s Bureau; Self; Abbott Diabetes, Amgen Inc., Ascensia Diabetes Care, Lilly Diabetes, Sanofi-Aventis. A. Aljawhrji: None. M. R. Alsubaiee: None. H. A. Zarif: Advisory Panel; Self; Pfizer Foundation, Speaker’s Bureau; Self; Medtronic. S. B. Alaidarous: Other Relationship; Self; AstraZeneca, Novo Nordisk. S. A. Khashwayn: None. Funding King Abdullah International Research Center |
| تدمد: | 1939-327X 0012-1797 0438-3990 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::6a44123e1428979489d597079228d215Test https://doi.org/10.2337/db21-152-orTest |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........6a44123e1428979489d597079228d215 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1939327X 00121797 04383990 |
|---|